Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CRNX, KALV, COGT, Cymabay Therapeutics, BIIB, and represent 42.54% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: AMLX (+$16M), ANAB (+$10M), SNDX (+$9.2M), SRPT (+$7.8M), COGT (+$6.2M), BIIB (+$6.1M), CRNX (+$5.6M), ATXS, ITOS, KALV.
- Started 4 new stock positions in ANAB, AMLX, MRUS, Jasper Therapeutics.
- Reduced shares in these 6 stocks: Chinook Therapeutics (-$20M), APLS (-$9.8M), SAGE, Cymabay Therapeutics, MORF, SCLX.
- Sold out of its positions in APLS, Chinook Therapeutics, SAGE, SCLX.
- Saturn V Capital Management was a net buyer of stock by $53M.
- Saturn V Capital Management has $239M in assets under management (AUM), dropping by 32.51%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 20 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals In (CRNX) | 14.0 | $34M | +20% | 1.1M | 29.74 |
|
| Kalvista Pharmaceuticals (KALV) | 7.3 | $17M | +28% | 1.8M | 9.63 |
|
| Cogent Biosciences (COGT) | 7.2 | $17M | +55% | 1.8M | 9.75 |
|
| Cymabay Therapeutics | 7.0 | $17M | -5% | 1.1M | 14.91 |
|
| Biogen Idec (BIIB) | 7.0 | $17M | +57% | 65k | 257.01 |
|
| Amylyx Pharmaceuticals (AMLX) | 6.8 | $16M | NEW | 886k | 18.31 |
|
| Cytokinetics Com New (CYTK) | 6.1 | $15M | +21% | 495k | 29.46 |
|
| Sarepta Therapeutics (SRPT) | 6.0 | $14M | +119% | 118k | 121.22 |
|
| Horizon Therapeutics Pub L SHS | 5.4 | $13M | +11% | 111k | 115.69 |
|
| Syndax Pharmaceuticals (SNDX) | 4.9 | $12M | +365% | 808k | 14.52 |
|
| Iteos Therapeutics (ITOS) | 4.6 | $11M | +56% | 995k | 10.95 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 4.4 | $11M | +43% | 113k | 93.64 |
|
| Anaptysbio Inc Common (ANAB) | 4.3 | $10M | NEW | 577k | 17.96 |
|
| BioMarin Pharmaceutical (BMRN) | 4.1 | $9.7M | +18% | 110k | 88.48 |
|
| Astria Therapeutics (ATXS) | 3.8 | $9.1M | +91% | 1.2M | 7.46 |
|
| BioCryst Pharmaceuticals (BCRX) | 2.9 | $7.0M | +2% | 983k | 7.08 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.1 | $5.0M | +146% | 10k | 491.63 |
|
| Morphic Hldg (MORF) | 1.3 | $3.1M | -10% | 137k | 22.91 |
|
| Jasper Therapeutics | 0.4 | $971k | NEW | 1.4M | 0.70 |
|
| Merus N V (MRUS) | 0.4 | $945k | NEW | 40k | 23.58 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023